Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis

The European Medicines Agency has approved a multicomponent serogroup B meningococcal vaccine (Bexsero®) for use in individuals of 2 months of age and older. A cost-effectiveness analysis (CEA) from the societal and Italian National Health Service perspectives was performed in order to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasparini, Roberto, Landa, Paolo, Amicizia, Daniela, Icardi, Giancarlo, Ricciardi, Walter, de Waure, Chiara, Tanfani, Elena, Bonanni, Paolo, Lucioni, Carlo, Testi, Angela, Panatto, Donatella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994748/
https://www.ncbi.nlm.nih.gov/pubmed/27163398
http://dx.doi.org/10.1080/21645515.2016.1160177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994748/
https://www.ncbi.nlm.nih.gov/pubmed/27163398
http://dx.doi.org/10.1080/21645515.2016.1160177

Ejemplares similares